Strides Pharma Science Ltd · NSE:STAR
Strides Pharma Science — Shareholder Meeting (September 2021)
21 slides from Strides Pharma Science's shareholder meeting presentation, Sep 3, 2021
Slide 1: Warm Welcome to Shareholders
Warm Welcome to Shareholders September 3, 2021
Slide 2: Agenda
AGENDA Strides at a Glance Financial Highlights for FY21 Business Highlights for FY21 Recent Updates Stelis Updates AGM Agenda
Slide 3: Strides - A Leading Global Pharma Company
Strides - A Leading Global Pharma Company 30+ YEARS 8 3,500+ 100+ 225+ Rich experience in the dynamic World-class manufacturing Global workforce Country of global sales R&D team size with global pharmaceutical industry facilities with all key regulatory strength presence across regulated development
Slide 4: Financial Highlights for FY21
Financial Highlights for FY21
Slide 5: Healthy financial performance in FY21 led by regulated markets
Healthy financial performance in FY21 led by regulated markets Revenue EBITDA Key financial highlights for FY21 (₹ in Million) (₹ in Million) 33,308 6,497 29% 21,936 25,880 Growth in consolidated 3,887 revenues for FY21 led by regulated markets 2,575 67% 29% 67% EBITDA growth driven by FY19 FY20 FY2
Slide 6: Strong balance sheet with steady improvement in ROCE
Strong balance Sheet with steady improvement in ROCE Consolidated Net Debt Net Debt To Equity Ratio Key balance sheet highlights (x times) (₹ in Million) and ROCE 0.76 22,885 0.46x 0.44 0.46 Healthy Net Debt to Equity 12,834 11,469 ratio at the end of FY21 1.98x FY19 FY20 FY21 FY19 FY20 FY21 Strong
Slide 7: Business Highlights for FY21
Business Highlights for FY21
Slide 8: US business delivers steady growth despite headwinds, revenues up 17%
US business delivers steady growth despite headwinds, revenues up 17% % of consolidated revenues in FY21 Growth in FY21 driven by improved revenue contribution from base molecules, new launches and VA business leveraging our Singapore facility US 48% Market COVID related headwinds witnessed in the m
Slide 9: Continued growth momentum in other regulated markets, revenues up 28%
Continued growth momentum in other regulated markets, revenues up 28% % of consolidated Revenues in FY21 Strong growth trajectory across other regulated markets for FY21 led by portfolio expansion and strengthening of frontend presence Other Reg Markets 32% Healthy scale of supplies to Arrotex in Au
Slide 10: Emerging markets returns to growth in FY21 with 73% jump in revenues
Emerging markets returns to growth in FY21 with 73% jump in revenues % of consolidated Revenues in FY21 Post a strategic reset, Africa business returned to healthy growth during FY21 with a sharper focus on supply chain execution 20% Emerging Markets Selective expansion of footprint with new launche
Slide 11: Recent Updates
Recent Updates
Slide 12: Industry headwinds currently impacting performance across markets
Industry headwinds currently impacting performance across markets Sector Headwinds Implications for Strides Mitigation Strategies US Business o Major headwinds faced by the sector o Witnessed double digit price erosion in US o Strides announced acquisition of basket of ANDAs and manufacturing site a
Slide 13: Portfolio more than doubles our current basket of 100 approved ANDAs
Acquisition of ANDA portfolio from Endo solves for headwinds Portfolio more than doubles our current basket of 100 approved ANDA’s • Strides will pay ~US$24m for the acquisition of basket of ANDAs and the manufacturing facility at Chestnut Ridge, NY Transaction Details • The transaction will be fina
Slide 14: Acquisition of world class multi-dosage facility at Chestnut Ridge, New York
Acquisition of world class multi-dosage facility at Chestnut Ridge, New York Built over an area of ~200,000 sq ft, the site adds new growth capacities of 2 billion units for the US markets Site expands our capabilities into niche domains including Hormones, Nasal Sprays, Gels, Modified Release produ
Slide 15: Stelis Updates
Stelis Updates
Slide 16: Global CDMO services business
Global CDMO services business Drug Product block commercialized with On track to receive all major regulatory Microbial drug substance block already healthy order book for the next 18-24 months approvals in FY22 validated and attracting commercial traction • Drug product block running on high-capaci
Slide 17: Integrated global vaccine CDMO business with large capacity and diverse capability
Integrated global vaccine CDMO business with large capacity and diverse capability Diversified vaccine play Update on Sputnik V Evaluating new vaccine partnerships Capabilities DS DP • rAD5 and rAD26 components of the vaccine • Significant ongoing interest and have been validated on the small scale
Slide 18: Own Products - Targeting 6 molecules in phase 1 with combined market size of USD 40b
Own Products - Targeting 6 molecules in phase 1 with combined market size of USD 40b Development Molecule Market Size ($b) Indication Latest Update Stage Filed in EU/ • EU file for MAA under review cycle, expected closure by Q4FY22 STLP001 ~2 Osteoporosis Phase 1 ready for • More than 20 companies a
Slide 19: AGM Agenda
AGM Agenda
Slide 20: Agenda for the AGM
Agenda for the AGM Ordinary Adoption of Audited Financial Statements for the Financial Year ended March 31, 2021 Business Ordinary Declaration of Dividend for the Financial Year ended March 31, 2021 Business Ordinary Re-Appointment of Mr. Deepak Vaidya, retiring director, as a Non-Executive Director
Slide 21: Thank You
Thank You Strides Pharma Science Limited CORPORATE OFFICE 201, Devavrata, Sector 17, Vashi, Navi Mumbai - 400 703, India Tel.: +91 22 2789 2924/2789 3199 Email: [email protected] Website: www.strides.com CIN: L24230MH1990PLC057062 REGISTERED OFFICE Bannerghatta Road, Bengaluru - 560 076, India Te
Strides Pharma Science — Shareholder Meeting (September 2021) on 6ix